MedPlus Health Services Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022
February 03, 2023 at 07:36 am
Share
MedPlus Health Services Limited reported earnings results for the third quarter and nine months ended December 31, 2022. For the third quarter, the company reported sales was INR 11,903.14 million compared to INR 9,334.53 million a year ago. Revenue was INR 12,016.75 million compared to INR 9,407.87 million a year ago. Net income was INR 134.07 million compared to INR 171.73 million a year ago. Basic earnings per share from continuing operations was INR 1.12 compared to INR 1.53 a year ago. Diluted earnings per share from continuing operations was INR 1.12 compared to INR 1.52 a year ago.
For the nine months, sales was INR 33,045.93 million compared to INR 28,133.72 million a year ago. Revenue was INR 33,369.77 million compared to INR 28,316.86 million a year ago. Net income was INR 231.8 million compared to INR 840.74 million a year ago. Basic earnings per share from continuing operations was INR 2.16 compared to INR 7.66 a year ago. Diluted earnings per share from continuing operations was INR 2.16 compared to INR 7.44 a year ago.
MedPlus Health Services Limited is an India-based omni channel retail pharmacy. The Company is primarily engaged in retail trading of medicines and general items, wholesale cash and carry and pathological laboratory testing services, wholesale trading and manufacturing of pharmaceutical products, fast-moving consumer goods and beauty products. It operates through two segments: Retail and Diagnostics. The Retail segment is engaged in retail trading of medicines and general items. The Diagnostics segment is engaged in the diagnostic services. The Company operates approximately 3,882 stores in 552 cities distributed across Tamil Nadu, Andhra Pradesh, Telangana, Karnataka, Odisha, West Bengal, and Maharashtra. Its omni-channel platform enables the Company to service its customers through its stores, as well as its online channels. Its subsidiaries include Optival Health Solutions Private Limited, MHS Pharmaceuticals Private Limited, Kalyani Meditimes Private Limited, and others.